ITCI Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 3.40%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $43,934,823.19

Intra-Cellular Therapies Insider Trading History Chart

Intra-Cellular Therapies Share Price & Price History

^$72.30

▼ -0.96 (-1.31%)

As of 04/29/2024 01:00 AM ET

Days: 30 | 90 | 365

Charles Payne’s Gift to Stock Investors

From Unstoppable Prosperity | Ad

Right now, millions of good honest folks are feeling the squeeze. Last year's terrible market did a number on their accounts. Stock values plunged. Retirement accounts lost too.

Watch Insider's Advantage Event Tuesday at 4:00 PM ET

Intra-Cellular Therapies Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/11/2024	Lawrence J. Hineline	CFO	Sell	10,121	$65.96	$667,581.16
3/11/2024	Michael Halstead	EVP	Sell	7,345	$65.97	$484,549.65	19,803
3/11/2024	Sharon Mates	CEO	Sell	20,565	$65.21	$1,341,043.65	1,050,309
3/7/2024	Lawrence J. Hineline	CFO	Sell	13,132	$66.60	$874,591.20	29,700
3/7/2024	Sharon Mates	CEO	Sell	40,712	$66.50	$2,707,348.00	1,050,309
3/7/2024	Suresh K. Durgam	EVP	Sell	6,450	$66.56	$429,312.00	16,170
2/26/2024	Joel S. Marcus	Director	Sell	26,328	$68.68	$1,808,207.04	39,662
2/26/2024	Lawrence J. Hineline	CFO	Sell	13,337	$69.43	$925,987.91
2/26/2024	Michael Halstead	EVP	Sell	7,907	$69.53	$549,773.71	29,700
2/26/2024	Sharon Mates	CEO	Sell	22,590	$69.79	$1,576,556.10	1,050,309
1/18/2024	Sharon Mates	CEO	Sell	67,917	$65.19	$4,427,509.23	1,050,309
1/16/2024	Sharon Mates	CEO	Sell	75,361	$67.25	$5,068,027.25	1,050,309
1/11/2024	Michael Halstead	EVP	Sell	50,000	$66.83	$3,341,500.00
1/2/2024	Suresh K. Durgam	EVP	Sell	62,282	$70.60	$4,397,109.20
12/13/2023	Suresh K. Durgam	EVP	Sell	21,262	$65.00	$1,382,030.00
11/6/2023	Mark Neumann	EVP	Sell	42,393	$55.63	$2,358,322.59	29,700
9/18/2023	Sharon Mates	CEO	Sell	55,587	$53.76	$2,988,357.12	1,094,722
8/7/2023	Mark Neumann	EVP	Sell	55,300	$58.79	$3,251,087.00	45,339
7/17/2023	Suresh K. Durgam	EVP	Sell	1,842	$65.00	$119,730.00	21,262
6/14/2023	Lawrence J. Hineline	CFO	Sell	81,854	$63.97	$5,236,200.38
4/17/2023	Robert L. Van Nostrand	Director	Sell	10,000	$63.00	$630,000.00	9,345
3/28/2023	Mark Neumann	EVP	Sell	15,604	$54.31	$847,453.24	45,339
3/13/2023	Lawrence J. Hineline	CFO	Sell	5,582	$44.93	$250,799.26
3/13/2023	Sharon Mates	CEO	Sell	20,565	$44.99	$925,219.35	1,130,309
3/13/2023	Suresh K. Durgam	EVP	Sell	7,344	$45.04	$330,773.76	23,104
3/10/2023	Lawrence J. Hineline	CFO	Sell	15,663	$43.06	$674,448.78
3/10/2023	Mark Neumann	EVP	Sell	8,550	$43.34	$370,557.00	57,357
3/10/2023	Sharon Mates	CEO	Sell	41,770	$43.15	$1,802,375.50	1,130,309
3/1/2023	Mark Neumann	EVP	Sell	7,241	$50.01	$362,122.41	49,199
2/24/2023	Lawrence J. Hineline	CFO	Sell	7,455	$47.03	$350,608.65
2/24/2023	Mark Neumann	EVP	Sell	4,046	$47.12	$190,647.52	56,440
2/24/2023	Sharon Mates	CEO	Sell	22,590	$47.03	$1,062,407.70	1,100,309
2/24/2023	Suresh K. Durgam	SVP	Sell	7,906	$47.14	$372,688.84	23,104
2/21/2023	Lawrence J. Hineline	CFO	Sell	10,443	$46.82	$488,941.26
2/21/2023	Mark Neumann	EVP	Sell	3,898	$47.01	$183,244.98	52,580
2/21/2023	Sharon Mates	CEO	Sell	27,848	$46.83	$1,304,121.84	1,100,309
2/21/2023	Suresh K. Durgam	SVP	Sell	8,354	$46.84	$391,301.36	23,104
2/17/2023	Lawrence J. Hineline	CFO	Sell	53,968	$49.83	$2,689,225.44
12/19/2022	Joel S. Marcus	Director	Sell	5,000	$50.82	$254,100.00	29,233
12/13/2022	Sharon Mates	CEO	Sell	33,083	$55.00	$1,819,565.00	1,100,309
12/1/2022	Michael Halstead	EVP	Sell	50,000	$53.73	$2,686,500.00
9/21/2022	Lawrence J. Hineline	CFO	Sell	65,164	$45.63	$2,973,433.32
8/11/2022	Robert L. Van Nostrand	Director	Sell	30,000	$57.13	$1,713,900.00	9,043
5/12/2022	Joel S. Marcus	Director	Sell	10,000	$55.00	$550,000.00	54,233
4/8/2022	Mark Neumann	EVP	Sell	86,348	$64.37	$5,558,220.76	45,339
3/18/2022	Rory B. Riggs	Director	Sell	20,637	$61.18	$1,262,571.66
3/16/2022	Rory B. Riggs	Director	Sell	64,534	$59.27	$3,824,930.18
3/7/2022	Joel S. Marcus	Director	Sell	5,000	$54.52	$272,600.00
3/4/2022	Suresh K. Durgam	Insider	Sell	3,860	$55.52	$214,307.20
3/2/2022	Suresh K. Durgam	Insider	Sell	4,177	$56.98	$238,005.46
2/24/2022	Lawrence J. Hineline	CFO	Sell	7,454	$51.97	$387,384.38
2/24/2022	Mark Neumann	EVP	Sell	7,906	$52.21	$412,772.26
2/24/2022	Sharon Mates	CEO	Sell	22,589	$51.98	$1,174,176.22
2/24/2022	Suresh K. Durgam	Insider	Sell	4,046	$52.27	$211,484.42
2/22/2022	Lawrence J. Hineline	CFO	Sell	10,443	$55.40	$578,542.20
2/22/2022	Mark Neumann	EVP	Sell	11,139	$55.29	$615,875.31
2/22/2022	Sharon Mates	CEO	Sell	27,847	$55.39	$1,542,445.33
2/22/2022	Suresh K. Durgam	Insider	Sell	4,177	$55.29	$230,946.33
1/18/2022	Suresh K. Durgam	Insider	Sell	6,223	$42.03	$261,552.69
1/10/2022	Lawrence J. Hineline	CFO	Sell	19,639	$40.76	$800,485.64
1/10/2022	Mark Neumann	EVP	Sell	20,948	$40.78	$854,259.44
1/10/2022	Sharon Mates	CEO	Sell	41,896	$40.78	$1,708,518.88
1/10/2022	Suresh K. Durgam	Insider	Sell	6,870	$40.76	$280,021.20
12/21/2021	Lawrence J. Hineline	CFO	Sell	175,000	$47.59	$8,328,250.00
12/21/2021	Michael Halstead	EVP	Sell	176,863	$47.56	$8,411,604.28
10/18/2021	Mark Neumann	EVP	Sell	13,448	$40.86	$549,485.28
10/18/2021	Sharon Mates	CEO	Sell	8,192	$40.00	$327,680.00
10/15/2021	Sharon Mates	CEO	Sell	40,392	$40.00	$1,615,680.00
6/14/2021	Joel S. Marcus	Director	Sell	18,289	$42.27	$773,076.03	13,767
5/27/2021	Christopher D. Alafi	Director	Sell	8,482	$40.01	$339,364.82	346,795
5/24/2021	Christopher D. Alafi	Director	Sell	26,575	$40.47	$1,075,490.25	346,795
5/21/2021	Christopher D. Alafi	Director	Sell	1,100	$40.00	$44,000.00	346,795

The “Next Bitcoin”? 10 CENT Crypto Set to Explode

From True Market Insiders | Ad

The man who bought Bitcoin and Ethereum in 2017… and has spotted 44 different coins that have returned over 100%... Is now exposing a 10-cent coin that just partnered with Amazon…

Click For My #1 FREE Crypto for 2024

SEC Filings (Institutional Ownership Changes) for Intra-Cellular Therapies (NASDAQ:ITCI)

92.33% of Intra-Cellular Therapies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Intra-Cellular Therapies Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
4/29/2024	China Universal Asset Management Co. Ltd.	18,613	$1.29M	0.2%	+67.2%	0.019%
4/26/2024	Pinnacle Associates Ltd.	173,892	$12.03M	0.2%	-1.3%	0.180%
4/24/2024	Gemmer Asset Management LLC	4,000	$0.28M	0.0%	-33.3%	0.004%
4/24/2024	Assenagon Asset Management S.A.	649,817	$44.97M	0.1%	-14.9%	0.671%
4/23/2024	Global Retirement Partners LLC	765	$53K	0.0%	-39.3%	0.001%
4/22/2024	PFG Investments LLC	13,800	$0.96M	0.1%	+392.9%	0.014%
4/22/2024	Raymond James & Associates	156,046	$10.80M	0.0%	+12.4%	0.161%
4/19/2024	Handelsinvest Investeringsforvaltning	3,217	$0.22M	0.1%	-34.2%	0.003%
4/18/2024	Wasatch Advisors LP	3,854,747	$266.75M	1.4%	+6.3%	3.982%
4/18/2024	Allspring Global Investments Holdings LLC	16,374	$1.13M	0.0%	-28.9%	0.017%
4/17/2024	Hennion & Walsh Asset Management Inc.	16,651	$1.15M	0.1%	+14.4%	0.017%
4/5/2024	First Hawaiian Bank	5,973	$0.41M	0.0%	-2.8%	0.006%
4/5/2024	Los Angeles Capital Management LLC	16,024	$1.11M	0.0%	-8.8%	0.017%
3/29/2024	Kapitalo Investimentos Ltda	368	$26K	0.0%	N/A	0.000%
3/26/2024	HighPoint Advisor Group LLC	3,199	$0.22M	0.0%	N/A	0.003%
3/22/2024	PNC Financial Services Group Inc.	3,795	$0.27M	0.0%	-5.9%	0.004%
3/11/2024	Vanguard Group Inc.	9,094,302	$651.33M	0.0%	+6.5%	9.394%
3/5/2024	Wellington Management Group LLP	1,763,475	$126.30M	0.0%	-2.9%	1.822%
3/1/2024	Goldman Sachs Group Inc.	578,615	$41.44M	0.0%	+52.6%	0.598%
2/28/2024	American International Group Inc.	46,576	$3.34M	0.0%	-0.4%	0.048%
2/26/2024	Virtu Financial LLC	7,623	$0.55M	0.0%	N/A	0.008%
2/26/2024	Perceptive Advisors LLC	108,000	$7.74M	0.2%	N/A	0.112%
2/20/2024	Quarry LP	1,000	$72K	0.0%	-69.7%	0.001%
2/15/2024	Parkman Healthcare Partners LLC	186,272	$13.34M	1.9%	N/A	0.194%
2/15/2024	Great Point Partners LLC	110,607	$7.92M	1.4%	-50.8%	0.115%
2/14/2024	Avidity Partners Management LP	710,000	$50.85M	1.9%	-11.4%	0.738%
2/14/2024	Wasatch Advisors LP	3,627,308	$259.79M	1.4%	-4.6%	3.769%
2/14/2024	Bellevue Group AG	3,066,400	$219.62M	3.4%	-3.3%	3.186%
2/14/2024	Avoro Capital Advisors LLC	2,255,555	$161.54M	2.2%	N/A	2.344%
2/14/2024	Lighthouse Investment Partners LLC	62,450	$4.47M	0.2%	N/A	0.065%
2/14/2024	Regal Investment Advisors LLC	14,501	$1.04M	0.1%	+6.5%	0.015%
2/14/2024	Sectoral Asset Management Inc.	7,420	$0.53M	0.2%	-94.0%	0.008%
2/14/2024	Schroder Investment Management Group	779,823	$55.85M	0.1%	+36.7%	0.810%
2/14/2024	AdvisorShares Investments LLC	4,151	$0.30M	0.1%	-28.1%	0.004%
2/13/2024	DCF Advisers LLC	96,857	$6.94M	3.8%	-9.6%	0.101%
2/13/2024	Rhenman & Partners Asset Management AB	90,000	$6.45M	0.6%	-5.3%	0.094%
2/13/2024	California State Teachers Retirement System	92,450	$6.62M	0.0%	-4.7%	0.096%
2/12/2024	Eagle Asset Management Inc.	435,718	$31.21M	0.2%	+5.5%	0.453%
2/12/2024	Alpha DNA Investment Management LLC	8,147	$0.58M	0.2%	N/A	0.008%
2/12/2024	Evoke Wealth LLC	24,391	$1.75M	0.0%	N/A	0.025%
2/12/2024	TD Asset Management Inc	72,648	$5.20M	0.0%	N/A	0.075%
2/12/2024	1492 Capital Management LLC	35,293	$2.53M	1.4%	+1.0%	0.037%
2/12/2024	Parallel Advisors LLC	1,564	$0.11M	0.0%	+16.3%	0.002%
2/12/2024	Cape Investment Advisory Inc.	1,085	$78K	0.0%	N/A	0.001%
2/9/2024	Orion Portfolio Solutions LLC	25,105	$1.80M	0.0%	-8.0%	0.026%
2/9/2024	Franklin Resources Inc.	1,780,160	$127.50M	0.1%	-0.4%	1.850%
2/9/2024	Assetmark Inc.	2,236	$0.16M	0.0%	+17.8%	0.002%
2/9/2024	GW&K Investment Management LLC	1,628,244	$116.62M	1.1%	-3.8%	1.692%
2/9/2024	Trexquant Investment LP	78,876	$5.65M	0.1%	+4.0%	0.082%
2/9/2024	Clearbridge Investments LLC	1,553,135	$111.24M	0.1%	+10.7%	1.614%
2/9/2024	Coldstream Capital Management Inc.	3,690	$0.26M	0.0%	N/A	0.004%
2/9/2024	UBS Group AG	134,762	$9.65M	0.0%	+205.3%	0.140%
2/9/2024	PNC Financial Services Group Inc.	3,795	$0.27M	0.0%	-5.9%	0.004%
2/9/2024	Norges Bank	1,197,203	$85.74M	0.0%	N/A	1.244%
2/8/2024	Great Lakes Advisors LLC	149,552	$10.71M	0.1%	-1.2%	0.155%
2/8/2024	Panagora Asset Management Inc.	6,729	$0.48M	0.0%	N/A	0.007%
2/8/2024	EFG Asset Management North America Corp.	32,354	$2.32M	0.4%	-2.4%	0.034%
2/8/2024	Vanguard Personalized Indexing Management LLC	5,380	$0.39M	0.0%	+36.3%	0.006%
2/8/2024	Nicholas Investment Partners LP	50,244	$3.60M	0.4%	-85.0%	0.052%
2/8/2024	First Turn Management LLC	217,425	$15.57M	2.2%	N/A	0.226%
2/8/2024	Pinnacle Wealth Planning Services Inc.	2,905	$0.21M	0.0%	N/A	0.003%
2/8/2024	Essex Investment Management Co. LLC	1,729	$0.12M	0.0%	-18.0%	0.002%
2/7/2024	Principal Financial Group Inc.	460,566	$32.99M	0.0%	+10.7%	0.479%
2/7/2024	Jump Financial LLC	14,600	$1.05M	0.0%	-74.3%	0.015%
2/7/2024	BNP Paribas Financial Markets	264,276	$18.93M	0.0%	-17.6%	0.275%
2/7/2024	Teacher Retirement System of Texas	20,007	$1.43M	0.0%	-18.3%	0.021%
2/7/2024	Van Hulzen Asset Management LLC	5,700	$0.41M	0.0%	-5.0%	0.006%
2/7/2024	TimesSquare Capital Management LLC	496,350	$35.55M	0.5%	-1.1%	0.516%
2/6/2024	Charles Schwab Investment Management Inc.	993,813	$71.18M	0.0%	+1.9%	1.033%
2/6/2024	Lisanti Capital Growth LLC	52,885	$3.79M	0.9%	N/A	0.055%
2/6/2024	M&T Bank Corp	4,780	$0.34M	0.0%	+19.3%	0.005%
2/6/2024	Amalgamated Bank	13,394	$0.96M	0.0%	-6.5%	0.014%
2/6/2024	Los Angeles Capital Management LLC	17,574	$1.26M	0.0%	+14.4%	0.018%
2/6/2024	Natixis Advisors L.P.	33,888	$2.43M	0.0%	+8.2%	0.035%
2/6/2024	Swiss National Bank	170,400	$12.20M	0.0%	-10.2%	0.177%
2/6/2024	New York Life Investment Management LLC	10,656	$0.76M	0.0%	N/A	0.011%
2/5/2024	Victory Capital Management Inc.	65,956	$4.72M	0.0%	-2.3%	0.069%
2/5/2024	Mach 1 Financial Group LLC	7,180	$0.51M	0.2%	N/A	0.007%
2/5/2024	AtonRa Partners	5,772	$0.41M	0.8%	-8.9%	0.006%
2/5/2024	Russell Investments Group Ltd.	15,317	$1.10M	0.0%	+97.8%	0.016%
2/2/2024	Truist Financial Corp	64,024	$4.59M	0.0%	+3.4%	0.067%
2/2/2024	Bailard Inc.	17,080	$1.22M	0.0%	+1.2%	0.018%
2/1/2024	New York State Common Retirement Fund	57,572	$4.12M	0.0%	+9.6%	0.060%
2/1/2024	California Public Employees Retirement System	160,376	$11.49M	0.0%	+14.2%	0.167%
2/1/2024	OLD National Bancorp IN	20,785	$1.49M	0.0%	-3.8%	0.022%
2/1/2024	Shikiar Asset Management Inc.	3,500	$0.25M	0.1%	N/A	0.004%
2/1/2024	Handelsbanken Fonder AB	18,500	$1.33M	0.0%	+6.3%	0.019%
2/1/2024	Signaturefd LLC	518	$37K	0.0%	+85.7%	0.001%
1/31/2024	abrdn plc	58,695	$4.20M	0.0%	N/A	0.061%
1/31/2024	Knights of Columbus Asset Advisors LLC	54,499	$3.90M	0.3%	+100.6%	0.057%
1/31/2024	Calamos Advisors LLC	8,152	$0.58M	0.0%	N/A	0.008%
1/31/2024	Xponance Inc.	5,676	$0.41M	0.0%	+3.0%	0.006%
1/30/2024	Quantum Private Wealth LLC	23,705	$1.70M	0.7%	+64.7%	0.025%
1/30/2024	HealthInvest Partners AB	12,245	$0.88M	0.7%	N/A	0.013%
1/30/2024	Zurcher Kantonalbank Zurich Cantonalbank	18,738	$1.34M	0.0%	+36.1%	0.019%
1/30/2024	Mackenzie Financial Corp	4,037	$0.29M	0.0%	N/A	0.004%
1/30/2024	Strs Ohio	26,300	$1.88M	0.0%	-5.7%	0.027%
1/30/2024	Phocas Financial Corp.	27,210	$1.95M	0.3%	N/A	0.028%
1/26/2024	Cerity Partners LLC	3,710	$0.27M	0.0%	N/A	0.004%
1/26/2024	Mutual of America Capital Management LLC	50,202	$3.60M	0.0%	-4.4%	0.052%

Data available starting January 2016

Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.

Today's Range

Now: $72.30

$71.97

$73.82

50 Day Range

MA: $69.27

$64.37

$79.84

52 Week Range

Now: $72.30

$45.50

$84.89

Volume

552,276 shs

Average Volume

934,089 shs

Market Capitalization

$7.00 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.02

Who are the company insiders with the largest holdings of Intra-Cellular Therapies?: Intra-Cellular Therapies' top insider shareholders include:
Sharon Mates (CEO)
Mark Neumann (EVP)
Joel S Marcus (Director)
Lawrence J Hineline (CFO)
Michael Halstead (EVP)
Suresh K Durgam (EVP)
Suresh K Durgam (SVP)
Nostrand Robert L Van (Director)
Suresh K Durgam (EVP)
Learn More about top insider investors at Intra-Cellular Therapies.
Who are the major institutional investors of Intra-Cellular Therapies?: Intra-Cellular Therapies' top institutional shareholders include:
Wasatch Advisors LP — 3.98%
Assenagon Asset Management S.A. — 0.67%
Principal Financial Group Inc. — 0.54%
Pinnacle Associates Ltd. — 0.18%
Raymond James & Associates — 0.16%
Simplex Trading LLC — 0.00%
Learn More about top institutional investors of Intra-Cellular Therapies stock.
Which institutional investors are selling Intra-Cellular Therapies stock?: In the previous quarter, ITCI stock was sold by these institutional investors:
Assenagon Asset Management S.A.
Allspring Global Investments Holdings LLC
Pinnacle Associates Ltd.
Gemmer Asset Management LLC
Handelsinvest Investeringsforvaltning
Los Angeles Capital Management LLC
Global Retirement Partners LLC
First Hawaiian Bank
During the last year, company insiders that have sold Intra-Cellular Therapies company stock include:
Sharon Mates (CEO)
Mark Neumann (EVP)
Joel S Marcus (Director)
Lawrence J Hineline (CFO)
Michael Halstead (EVP)
Suresh K Durgam (EVP)
Suresh K Durgam (SVP)
Learn More investors selling Intra-Cellular Therapies stock.
Which institutional investors are buying Intra-Cellular Therapies stock?: During the last quarter, ITCI stock was acquired by institutional investors including:
Wasatch Advisors LP
Simplex Trading LLC
Principal Financial Group Inc.
Raymond James & Associates
PFG Investments LLC
China Universal Asset Management Co. Ltd.
Hennion & Walsh Asset Management Inc.